Oramed Pharmaceuticals (ORMP) Common Equity (2011 - 2026)

Oramed Pharmaceuticals' Common Equity history runs 16 years deep, the most recent figure standing at $238.3 million for Q1 2026.

• Quarterly Common Equity rose 70.33% year-over-year to $238.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $238.3 million (up 70.33% YoY) and the FY2025 annual result came in at $199.7 million, up 37.43% from the prior year.
• Common Equity was $238.3 million for Q1 2026 at Oramed Pharmaceuticals, up from $199.7 million in the prior quarter.
• Across five years, Common Equity topped out at $238.3 million in Q1 2026 and bottomed at $139.9 million in Q1 2025.
• A 5-year average of $165.2 million and a median of $153.6 million in 2025 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2025 — Common Equity declined 15.58% — and 2026, when it soared 70.33%.
• Oramed Pharmaceuticals' Common Equity stood at $151.2 million in 2022, then gained by 7.76% to $162.9 million in 2023, then slipped by 10.77% to $145.3 million in 2024, then surged by 37.43% to $199.7 million in 2025, then rose by 19.29% to $238.3 million in 2026.
• Business Quant data shows ORMP's Common Equity at $238.3 million in Q1 2026, $199.7 million in Q4 2025, and $203.3 million in Q3 2025.